OGN Organon and Co

   By Stephen Nakrosis 
 

Shares of biopharmaceutical company ObsEva SA rose on Tuesday, after the company said it entered a deal which will see Organon & Co. license the global development, manufacturing and commercial rights to ebopiprant.

At 3:20 p.m. ET, shares of ObsEva advanced 10.52% to $2.78. Volume topped 66.1 million shares, above the stock's 65-day average volume of 678,428.

At 3:17 p.m. ET, shares of Organon & Co. slid 2.07% to $29.03.

Ebopiprant is being evaluated as a potential treatment for preterm labor by reducing inflammation and uterine contractions, Organon said.

-Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

July 27, 2021 15:46 ET (19:46 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.